Yexiang Sun

Yexiang Sun


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
HZHouyu Zhao
Houyu Zhao
LZLin Zhuo
Lin Zhuo
YSYexiang Sun
Yexiang Sun
PSPeng Shen
Peng Shen
HLHongbo Lin
Hongbo Lin
SZSiyan Zhan
Siyan Zhan
The health burden of Parkinson’s disease (PD) and diabetes increases rapidly in China. However, no population-based study of the association between glucose lowering agents and PD incidence has been conducted in mainland Chinese population. Preclinical studies indicate that thiazolidinediones (TZDs) have neuroprotective effects against PD through stimulating peroxisome proliferator-activated receptor gamma. Nevertheless, debate remains in human studies. We assembled a retrospective cohort of type 2 diabetes mellitus (T2DM) patients who were new users of TZDs or alpha glucosidase inhibitors (AGIs) using the Yinzhou Regional Health Care Database. A Cox model with inverse probability of treatment weighting (IPTW) was applied to estimate the hazard ratio (HR) of PD incidence associated with the use of TZDs compared with AGIs. The final cohort included 12,704 new users of TZDs and 49,696 new users of AGIs. The incidence of PD was 135 per 100,000 person-years in TZD users and 203 per 100,000 person-years in the AGI group. An inverse association between use of TZDs and incidence of PD, with a HR of 0.74 (95% confidence interval, 0.59–0.92), was observed after adjusting for potential confounding using IPTW. The results of various subgroup analyses and sensitivity analyses were consistent with the findings of the primary analysis. Our results indicated that the use of TZD is associated with a decreased risk of PD incidence in a mainland Chinese population with T2DM. Given the heavy disease burden of PD and diabetes in China, these findings could provide some evidence for developing effective prevention and control measures to reduce the future incidence of PD in China.

13 May 2023 in Diabetologia
Verified
Journal Article
Closed access
PDF file
ZYZongming Yang
Zongming Yang
YWYonghao Wu
Yonghao Wu
LXLisha Xu
Lisha Xu
ZZZhanghang Zhu
Zhanghang Zhu
TLTiezheng Li
Tiezheng Li
KCKun Chen
Kun Chen

28 July 2025 in JMIR Medical Informatics
Verified
Journal Article
Open access
YZYongqi Zheng
Yongqi Zheng
MZMeng Zhang
Meng Zhang
CWConghui Wang
Conghui Wang
LGLing Gao
Ling Gao
JXJunqing Xie
Junqing Xie
FSFeng Sun
Feng Sun
Background: The adoption of common data models (CDMs) has transformed pharmacoepidemiologic research by enabling standardized data formatting and shared analytical tools across institutions. These models facilitate large-scale, multicenter studies and support timely real-world evidence generation. However, no comprehensive global evaluation of CDM applications in pharmacoepidemiology has been conducted. Objective: This study aimed to conduct a systematic review and bibliometric analysis to map the landscape of CDM usage in pharmacoepidemiology, including publication trends, institutional authors and collaborations, and citation impacts. Methods: In total, 5 English databases (PubMed, Web of Science, Embase, Scopus, and Virtual Health Library) and 4 Chinese databases (CNKI, Wan-Fang Data, VIP, and SinoMed) were searched for studies applying CDMs in pharmacoepidemiology from database inception to January 2024. Two reviewers independently screened studies and extracted information about basic publication details, methodological details, and exposure and outcome information. The studies were categorized into 2 groups according to their Total Citations per Year (TCpY), and a comparative analysis was conducted to examine the differences in characteristics between the 2 groups. Results: A total of 308 studies published between 1997 and 2024 were included, involving 1580 authors across 32 countries and 140 journals. The United States led in both publication volume and citation counts, followed by South Korea. Among the 10 most cited studies, 7 used the Vaccine Safety Datalink, 2 used Sentinel, and one used Observational Medical Outcomes Partnership. Studies were stratified by TCpY to reduce citation bias from publication timing. Comparative analysis showed that high-TCpY studies were significantly more associated with multicenter collaboration (P=.008), United States-based institutions (P=.04), and vaccine-related research (P=.009). These studies commonly featured larger sample sizes, cross-regional data, and enhanced generalizability. International collaborations primarily occurred among North America, Europe, and East Asia, with limited involvement from limited-income countries. Conclusions: This study presents the first bibliometric overview of CDM-based pharmacoepidemiologic research. The consistent output from United States institutions and increasing engagement from South Korea underscore their central roles in this field. High-TCpY studies tend to be multicenter, collaborative, and vaccine-focused, reflecting structural factors linked to research visibility and influence. Stratified citation analysis supports the value of real-world data integration and international cooperation in producing impactful studies. The dominance of limited-income countries in collaboration networks highlights a need for broader inclusion of underrepresented regions. These findings can help researchers identify key contributors, guide partner selection, and target appropriate journals. As CDM-based methods continue to expand, fostering diverse and collaborative research efforts will be crucial for advancing pharmacoepidemiologic knowledge globally.

11 March 2024 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
LZLin Zhang
Lin Zhang
ZYZiliang Yang
Ziliang Yang
YYYueqi Yin
Yueqi Yin
WHWenzan Huang
Wenzan Huang
TYTianfei Yi
Tianfei Yi
HLHongbo Lin
Hongbo Lin
Congenital heart disease (CHD) represents a significant population warranting particular attention concerning vaccination coverage. To comprehend the vaccination status of CHD within Yinzhou District, Ningbo City, China, and to facilitate the formulation of preventive, control, and immunization strategies against vaccine-preventable diseases in children with congenital heart conditions. Using the China Yinzhou Electronic Health Record Study (CHERRY) database, we analyzed the vaccination coverage of children with CHD born between January 1, 2016 and September 20, 2021, and analyzed the influencing factors associated with the level of vaccination coverage. This study involved 762 children diagnosed with CHD at the age of 12 months, revealing that 86.74% of these children had received at least one dose of the National Immunization Program (NIP) vaccines. The coverage for non-NIP vaccines, such as the rotavirus vaccine, influenza vaccine, Influenza Haemophilus influenzae Type b (Hib) Conjugate Vaccine, 13-valent pneumococcal conjugate vaccine (PCV13), and inactivated enterovirus type 71 vaccine (EV71), stood at 27.30%, 7.74%, 63.25%, 33.76%, and 34.51%, respectively. The completion coverage for the entire vaccination schedule were 27.30%, 5.51%, 55.77%, 34.25%, and 25.59%, respectively. There was a statistically significant correlation between vaccination coverage in classification of diagnostic medical institutions and the types of diagnosed diseases. Compared to their typically developing counterparts, 12-month-old children afflicted with CHD exhibit a slightly diminished vaccination coverage, alongside a discernible inclination toward delayed vaccination. Notably, the determination to undergo vaccinations seems predominantly influenced by the classification of diagnostic medical institutions. In practical terms, proactive measures involving early diagnosis, comprehensive health assessments, and timely interventions ought to be implemented to enhance vaccination rates while prioritizing safety.

14 May 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
TYTianfei Yi
Tianfei Yi
JZJunfeng Zhang
Junfeng Zhang
PSPeng Shen
Peng Shen
YSYexiang Sun
Yexiang Sun
Background: Acute respiratory infection syndromes (ARIs) pose major public health challenges due to their high infectivity, rapid transmission, and the lack of standardized definitions balancing sensitivity and specificity in current surveillance systems.Objective: Using data from Yinzhou Regional Health Information Platform (YRHIP), we refined ARIs definition, improved classical epidemic criteria and designed a comprehensive graded early-warning model to enhance early response capabilities.Methods: We optimized ARIs definition based on laboratory-confirmed cases and evaluating screening performance with clinical diagnoses. Anomaly detection methods, including historical limits method (HLM), moving percentile method (MPM), cumulative sum control chart (CUSUM), and exponentially weighted moving average (EWMA), were employed to develop a graded early-warning model. Syndrome selection and parameter tuning were guided by Youden’s index, agreement rate and F1-score.Results: The refined ARIs definition includes: Acute-phase fever with at least one typical respiratory symptoms; or acute-phase fever with at least two atypical respiratory symptoms; or at least one typical respiratory symptoms combined with at least two atypical respiratory symptoms. Furthermore, we demonstrate that ARIs outperform ILIs definition in early screening due to their broader symptom scope. By leveraging multidimensional time series data, we developed a robust epidemic criteria framework for early-warning models. The optimal early-warning parameters included configurations of HLM (K = 0.8), MPM (85th percentile), CUSUM(K = 0.7, H = 5), and EWMA (K = 3, λ = 0.05). The graded early-warning system revealed: Red early-warnings (all four models triggered) had the highest specificity; Orange early-warnings (at least three models triggered) demonstrated the best overall performance; Amber early-warnings (at least two models triggered) captured subtle trends; Green early-warnings (at least one model triggered) provided the highest sensitivity.Conclusion: This study establishes an optimized, multi-model-based framework for ARIs early-warning that balances sensitivity and specificity to strengthen public health management against diverse pathogens.

18 May 2026 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
CCChen Chen
Chen Chen
JHJingqin He
Jingqin He
HCHong Chen
Hong Chen
JTJialong Tan
Jialong Tan
XHXing Huang
Xing Huang
GLGordon G. Liu
Gordon G. Liu
Seasonal influenza remains a major global public health concern, causing substantial morbidity, mortality, and economic burden each year. China lacks age-stratified national estimates to inform vaccine policy and resource allocation, leaving an important evidence gap. Using a micro-costing approach, we calculated costs for each age group and then summed them from a societal perspective. The analysis was based on a real-world dataset of 12,784 laboratory-confirmed influenza cases. We estimated direct medical costs, direct non-medical costs, and productivity losses for both patients and caregivers. Deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) were conducted to assess model uncertainty. The annual economic burden of seasonal influenza in China was estimated at 8.82 billion USD (95% CI: 7.24-10.80 billion USD). Direct medical costs accounted for 1.84 billion USD, direct non-medical costs for 0.43 billion USD, and indirect costs for 6.55 billion USD. Under the human capital approach, indirect mortality costs were estimated at 3.79 billion USD. Applying the friction cost method reduced this estimate to approximately 0.27 billion USD. Children younger than 5 y contributed the most to outpatient costs, whereas adults aged 60 y and older accounted for the largest share of inpatient costs. These findings provide robust economic evidence to support the expansion of publicly funded influenza vaccination programs. High-burden groups, particularly children younger than 5 y and adults aged 60 y and older, should be prioritized to reduce the health and socioeconomic impact of influenza.